1009P Integrated biomarker analysis of brigatinib efficacy in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib

Abstract

The ALK inhibitor alectinib is a standard-of-care option for ALK+ NSCLC. However, most patients (pts) eventually develop disease progression on alectinib, often through the development of secondary ALK resistance mutations, such as G1202R. We present an exploratory integrated analysis of the impact of EML4-ALK fusion and secondary ALK mutations on efficacy with brigatinib from two phase 2 studies in alectinib-refractory ALK+ NSCLC.